Form 4: Ionis Pharma EVP Reports Stock Transactions, RSU Grants

Ionis Pharmaceuticals' EVP, Chief Clinical Development Officer Eugene Schneider reported recent acquisitions and dispositions of company stock, including new RSU and PRSU grants.

Summary

• Eugene Schneider, EVP, Chief Clinical Development Officer at Ionis Pharmaceuticals Inc. (IONS), reported several transactions involving company securities.
• On January 15, 2026, Schneider acquired 21,685 shares of Common Stock through the vesting and release of Restricted Stock Unit (RSU) awards.
• Following this acquisition, Schneider's direct beneficial ownership of Common Stock increased to 73,192 shares.
• On January 16, 2026, Schneider disposed of 9,302 shares of Common Stock at a weighted average price of $75.59 per share to cover tax withholding obligations related to the RSU vesting.
• The sale price ranged from $75.48 to $75.63 per share.
• After the sale, Schneider's direct beneficial ownership of Common Stock was 63,890 shares.
• Schneider was granted 25,800 Performance Restricted Stock Units (PRSUs) on January 15, 2026, under the company's 2011 Equity Incentive Plan.
• These PRSUs may vest over a three-year performance period based on the Issuer's relative total shareholder return compared to a peer group, with the reported number representing the maximum (200% of target).
• An additional 9,675 Restricted Stock Units (RSUs) were granted to Schneider on January 15, 2026, also under the 2011 Equity Incentive Plan.
• These RSUs vest in four equal annual installments, with payout in common stock or cash as determined by the company.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there was a sale of shares, it was for tax purposes, which is a neutral event. The significant grants of new Restricted Stock Units (RSUs) and Performance Restricted Stock Units (PRSUs) are positive, indicating ongoing executive compensation and alignment with future company performance, which generally signals confidence in the company's outlook.

Positives

• The acquisition of 21,685 shares of Common Stock through RSU vesting indicates a realization of previously granted equity compensation.
• The grant of 25,800 Performance Restricted Stock Units (PRSUs) aligns executive compensation with the company's long-term performance and shareholder returns.
• The grant of 9,675 Restricted Stock Units (RSUs) provides ongoing equity incentives and retention for a key executive.

Negatives

• The disposition of 9,302 shares of Common Stock, while for tax withholding, reduces the executive's direct beneficial ownership of the company's stock.

Risks

• The Performance Restricted Stock Units (PRSUs) are subject to vesting conditions based on the Issuer's relative total shareholder return, meaning the actual number of shares that will vest can range from zero to the maximum reported amount (25,800 PRSUs).
• The Restricted Stock Units (RSUs) vest over four equal annual installments, and the payout upon vesting may be in common stock or cash, which could introduce variability in the form of compensation received.

Future Outlook

The Performance Restricted Stock Units (PRSUs) granted on January 15, 2026, are designed to vest at the end of a three-year performance period, contingent on Ionis Pharmaceuticals' relative total shareholder return compared to a peer group. The actual number of PRSUs that will vest can vary from zero to the maximum reported amount of 25,800. The Restricted Stock Units (RSUs) granted on the same date are set to vest in four equal annual installments.

Industry Context

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of previously granted equity and new equity grants. Such filings are standard disclosures in the biotechnology and pharmaceutical industry, reflecting how companies incentivize and retain key talent through long-term equity plans. The structure of performance-based units is common for aligning executive interests with shareholder value creation.

Related Party Transactions

• The transactions involve equity compensation (RSUs and PRSUs) granted to an executive officer (Eugene Schneider) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan, which is a standard form of related party transaction for executive compensation.

Stakeholder Impact

• Shareholders: The grants of new equity (RSUs and PRSUs) could lead to minor dilution but also align the executive's interests with long-term shareholder value creation. The tax-related sale is a common event and not indicative of a change in executive sentiment.
• Employees: The equity grants to a key executive reinforce the company's compensation strategy, potentially influencing broader employee incentive programs.

Next Steps

• The Performance Restricted Stock Units (PRSUs) will be evaluated for vesting at the end of a three-year performance period, expiring on January 15, 2029.
• The Restricted Stock Units (RSUs) will vest in four equal annual installments, with the first installment expected on January 15, 2027.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, Performance Restricted Stock Units, Executive Compensation, Equity Incentive Plan, Eugene Schneider